Coya Therapeutics Inc(COYA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 5:27 PM ET (Korea 10/31 06:27)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1 | Insider Own | 14.69% | Shs Outstand | 23.5M | Perf Week | -8.38% |
| Market Cap | 0.08B | Forward P/E | - | EPS next Y | -9% | Insider Trans | - | Shs Float | 20.0M | Perf Month | -23.68% |
| Enterprise Value | 0.04B | PEG | - | EPS next Q | -0.34 | Inst Own | 33.13% | Short Float | 6.27% | Perf Quarter | -18.51% |
| Income | -0.02B | P/S | 10.56 | EPS this Y | -4.39% | Inst Trans | -1.8% | Short Ratio | 9.6 | Perf Half Y | -13.43% |
| Sales | 0.01B | P/B | 1.96 | EPS next 5Y | 5.4% | ROA | -53.66% | Short Interest | 1.25M | Perf YTD | -37.76% |
| Book/sh | 1.84 | P/C | 1.96 | EPS past 3/5Y | -1.01% -75.69% | ROE | -60.54% | 52W High | -45.47% ($6.62) | Perf Year | -41.01% |
| Cash/sh | 1.84 | P/FCF | - | Sales past 3/5Y | - | ROIC | -50.07% | 52W Low | -2.7% ($3.71) | Perf 3Y | -25.41% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 19.33% | Gross Margin | 99.76% | Volatility(W/M) | 5.93% 6.22% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 5.17 | Sales Y/Y TTM | 1793.76% | Oper. Margin | -260% | ATR (14) | 0.28 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 13.4 | EPS Q/Q | 22.34% | Profit Margin | -270.22% | RSI (14) | 27.52 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 13.4 | Sales Q/Q | 48.97% | SMA20 | -16.97% ($4.35) | Beta | 0.61 | Target Price | $15.21 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/11 | SMA50 | -21.72% ($4.61) | Rel Volume | 1.64 | Prev Close | $3.98 |
| Employees | 8 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 19% 45.08% | SMA200 | -22.24% ($4.64) | Avg Volume(3M) | 0.13M | Price | $3.61 |
| IPO | 2022/12/29 | Option/Short | Yes/Yes | Trades | 813 | Volume | 214,117 | Change | -9.3% |
🧬 Coya Therapeutics is a US-based clinical-stage biotech company developing immunomodulatory therapies based on the restoration of regulatory T cell (Treg) function. The company is building its own pipeline in the areas of neurodegenerative diseases and chronic inflammation, featuring an approach that targets immune homeostasis.
Over the past 1 year, on the lower side
45% below its 1-year high.
Traded more than usual. That is 164% of its average volume.
COYA has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -4.4% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,056. Peers typically go for $1,010.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -25.4%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 33.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #371 of 595 in the industry
Based on market cap of $85M.
EQ#370 Equillium Inc $87M PER - COYA#371 Coya Therapeutics Inc $85M PER - 
RLYB#372 Rallybio Corp $85M PER 3.5 
TNYA#373 Tenaya Therapeutics Inc $84M PER - 
RANI#374 Rani Therapeutics Holdings Inc $82M PER - 
FAQ
What kind of company is COYA?
COYA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of COYA?
The market cap of COYA is approximately $85M, ranking 4,553 within its sector.
What is the 52-week high and low for COYA?
COYA has recorded a 52-week high of $6.62 and a low of $3.71.
